Skip to main content

Table 3 Performance characteristics of anti-GP2 and ASCA IgA/IgG and PAB investigating 169 CD patients and 102 UC patients

From: Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn’s disease

  sensitivity 95% CI specificity 95% CI +LR 95% CI -LR 95% CI
anti-GP2 IgA 13.0 8.3–19.0 98.0 93.0–99.8 6.6 1.6–27.4 0.9 0.8–1.0
anti-GP2 IgG 28.4 21.7–35.8 92.2 85.1–96.6 3.6 1.8–7.3 0.8 0.7–0.9
anti-GP2 IgA or IgG 30.2 23.4–37.7 91.2 83.9–95.9 3.4 1.8–6.6 0.8 0.7–0.9
ASCA IgA 23.1 17.0–30.2 97.1 91.6–99.4 7.8 2.5–24.7 0.8 0.7–0.9
ASCA IgG 28.4 21.7–35.8 95.1 88.9–98.4 5.8 2.4–14.1 0.8 0.7–0.8
ASCA IgA or IgG 35.5 28.3–43.2 93.1 86.4–97.2 5.2 2.5–10.9 0.7 0.6–0.8
PAB ≥1/20 45.4 37.6–53.4 76.5 67.0–84.3 1.9 1.3–2.8 0.7 0.6–0.8
PAB ≥1/40 38.5 31.1–46.2 79.4 70.3–86.8 1.9 1.2–2.9 0.8 0.7–0.9
at least 1 ab* 50.9 43.1–58.6 85.3 76.9–91.5 3.5 2.1–5.6 0.6 0.5–0.7
at least 2 ab* 27.2 20.7–34.6 97.1 91.6–99.4 9.2 3.0–29.0 0.8 0.7–0.8
at least 3 ab* 10.6 6.4–16.3 100.0 96.4–100.0   0.9 0.8–0.9
at least 4 ab* 4.1 1.7–8.3 100.0 96.4–100.0   1.0 0.1–1.0
  1. Sensitivity, specificity and likelihood ratios were calculated using a cut-off of 20 U/ml for all ELISA and a titre of 1/20 and 1/40 of IIF.
  2. ab, antibody; ASCA, antibody to mannan of Saccharomyces cerevisiae; CD, Crohn’s disease; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; GP2, zymogen granule membrane glycoprotein 2; LR, likelihood ratio; PAB, pancreatic autoantibody; UC, ulcerative colitis; *anti GP2 and/ or ASCA.